After years of weight loss drug shortages, the FDA is saying there's now an adequate supply for most medications and they will be prohibiting like-for-like compounded versions.

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight loss drugs Mounjaro and Zepbound, in a matter of days. That’s because a federal judge has ruled that compounding pharmacies can’t keep making copies of the drug now that it’s no longer in shortage.

Very few people are currently being prescribed drugs for weight loss on the NHS in Scotland, research by BBC Scotland News has established. Medications like Mounjaro and Wegovy have been hailed as "game changers" for tackling obesity.

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their medications elsewhere.

The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of Novo Nordisk's weight-loss drug Wegovy until a federal court delivers its ruling in a lawsuit against the agency.

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.